Newtyn Management’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Newtyn Management’s Portfolio PRVL Stock Details PRVL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-153,617	Closed	-$3.54M	–	121
2020 Q4	$3.54M	Buy	+153,617	New	+$1.95M	0.82%	36

Newtyn Management's PRVL Position: Q1 2021 in Review

Newtyn Management sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 153,617 shares — an estimated $3.54M sold.

Newtyn Management first reported a position in PRVL in Q4 2020 and held it in 1 quarter. The position peaked at $3.54M in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

Newtyn Management reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Newtyn Management sold 153,617 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $3.54M.
Newtyn Management first reported a position in Prevail Therapeutics Inc. Common Stock in Q4 2020 and held it in 1 quarter.
Newtyn Management's Prevail Therapeutics Inc. Common Stock position peaked at $3.54M in Q4 2020.
0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on Newtyn Management's 13F filing for Q1 2021, filed 17 May 2021.